Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM-101PX in birch pollen allergy
NCT06037148Phase 1Completed
- Sponsor
- Desentum
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Hydrogel Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DM-101 in birch pollen allergy (4 arms), sponsored by Desentum. Primary endpoints: Treatment Emergent Adverse Events and Adverse Events of Special Interest. Started Sep 2023; status: completed.
02
Drugs
DM-101
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT06037148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037148.